AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22944391 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 21482702 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted cancer prevention education (audiovisual and written media)
Number of subjects: 105
Study 21482702 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 105)
Number of subjects: 105
Study 19586514 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser hair removal (LHR) using Nd:YAG laser after surgical excision of PNS, with 3 to 8 sessions (mean 4.87 ± 1.64) over a follow-up period of 12 to 23 months.
Number of subjects: 25
Study 19586514 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LHR treatment)
Number of subjects: 25
Study 19586514 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects of LHR treatment
Number of subjects: 25
Study 17197587 — intervention group
Group type: EXPERIMENTAL
Intervention: Teamwork training curriculum based on crew resource management
Number of subjects: 1307
Study 17197587 — intervention group
Group type: COMPARATOR
Intervention: Control group (no teamwork training)
Number of subjects: 1307
Study 17197587 — intervention group
Group type: EXPERIMENTAL
Intervention: Teamwork training
Number of subjects: 1307
Study 15344695 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide, 4 mg/day
Number of subjects: 68
Study 15344695 — intervention group
Group type: COMPARATOR
Intervention: Intravenous prednisolone, 120 mg/day
Number of subjects: 68
Study 15344695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 15344695 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone, 30 mg/day
Number of subjects: 68
Study 11174790 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical correction of the incompetent superficial femoral vein valve (in 64 extremities)
Number of subjects: 125
Study 11174790 — intervention group
Group type: COMPARATOR
Intervention: Phlebectomy (performed in all extremities)
Number of subjects: 125
Study 11174790 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrected valves (in 92% of the extremities with corrected valves)
Number of subjects: 125
Study 11174790 — intervention group
Group type: COMPARATOR
Intervention: Stable valvular function (in control group)
Number of subjects: 125
Study 11174790 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in superficial femoral vein reflux (in 74% of extremities with progressive clinical dynamics)
Number of subjects: 125
Study 11174790 — intervention group
Group type: COMPARATOR
Intervention: Increase in reflux after valvuloplasty (in 50% of extremities)
Number of subjects: 125
Study 9663215 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy-ALT-Trabeculectomy (TAT) sequence
Number of subjects: 591
Study 9663215 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser trabeculoplasty-trabeculectomy-trabeculectomy (ATT) sequence
Number of subjects: 591
Study 7677241 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedating antihistamines (triprolidine, diphenhydramine, clemastine)
Number of subjects: 0
Study 7677241 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsedating antihistamines (terfenadine, loratadine, cetirizine, acrivastine, mizolastine, ebastine)
Number of subjects: 0
Study 7677241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2509528 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant tissue-type plasminogen activator (rt-PA) administration
Number of subjects: 756
Study 1105174 — intervention group
Group type: EXPERIMENTAL
Intervention: L-PAM
Number of subjects: 211
Study 1105174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 31404623 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes-specific care (n = 88)
Number of subjects: 176
Study 31404623 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 88)
Number of subjects: 176
Study 28064150 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 21105
Study 28064150 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 21105
Study 28064150 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk prediction model (C-index = 0.693)
Number of subjects: 21105
Study 25400062 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel plus aspirin for 30 months
Number of subjects: 2191
Study 23873976 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose nicotine patch therapy (42mg/day)
Number of subjects: 52
Study 23873976 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 52
Study 21602625 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based training
Number of subjects: 0
Study 21602625 — intervention group
Group type: COMPARATOR
Intervention: Traditional instructor-led training
Number of subjects: 0
Study 19199072 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional verapamil
Number of subjects: 80
Study 19199072 — intervention group
Group type: COMPARATOR
Intervention: Local saline injection (control)
Number of subjects: 80
Study 16970513 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Number of subjects: 24000
Study 16970513 — intervention group
Group type: COMPARATOR
Intervention: Desloratadine
Number of subjects: 24000
Study 15381871 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc rhenium colloid
Number of subjects: 200
Study 15381871 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc phytate
Number of subjects: 200
Study 11104593 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA-EE (6 g/d)
Number of subjects: 33
Study 11104593 — intervention group
Group type: COMPARATOR
Intervention: Placebo (OA-EE; 6 g/d)
Number of subjects: 33
Study 9048692 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cancer outpatients (OPG1, OPG2, OPG3)
Number of subjects: 1231
Study 9048692 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cancer outpatients (OPG3)
Number of subjects: 1231
Study 9048692 — intervention group
Group type: COMPARATOR
Intervention: General population (CRG)
Number of subjects: 1231
Study 8363004 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking (smokers)
Number of subjects: 417
Study 8363004 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption (up to three or four drinks per day)
Number of subjects: 417
Study 8363004 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 417
Study 3088506 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil
Number of subjects: 45
Study 3088506 — intervention group
Group type: EXPERIMENTAL
Intervention: Ftorafur
Number of subjects: 45
Study 28987023 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble hyaluronic acid (HA) microneedle patch plus adenosine wrinkle cream
Number of subjects: 84
Study 28987023 — intervention group
Group type: COMPARATOR
Intervention: Soluble hyaluronic acid (HA) microneedle patch alone
Number of subjects: 84
Study 28987023 — intervention group
Group type: COMPARATOR
Intervention: Adenosine wrinkle cream alone
Number of subjects: 84
Study 27618935 — intervention group
Group type: EXPERIMENTAL
Intervention: Musical intervention applied during all NIV sessions
Number of subjects: 99
Study 27618935 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory deprivation during all NIV sessions
Number of subjects: 99
Study 27618935 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (control group)
Number of subjects: 99
Study 27618935 — intervention group
Group type: EXPERIMENTAL
Intervention: Musical intervention
Number of subjects: 99
Study 24928294 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial stewardship audit-and-feedback intervention
Number of subjects: 6
Study 24928294 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-ICU services without intervention)
Number of subjects: 6
Study 22397651 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue donepezil
Number of subjects: 295
Study 22397651 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 295
Study 22397651 — intervention group
Group type: COMPARATOR
Intervention: Discontinue donepezil
Number of subjects: 295
Study 22397651 — intervention group
Group type: COMPARATOR
Intervention: Donepezil and memantine combination
Number of subjects: 295
Study 20142596 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized prescribed total tumor dose (TTD) based on normal tissue dose constraints (mean lung dose, 19 Gy; maximal spinal cord dose, 54 Gy) up to a maximal TTD of 79.2 Gy in 1.8 Gy fractions twice daily
Number of subjects: 166
Study 18241646 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate combined with NP (vinorelbine and cisplatin)
Number of subjects: 120
Study 18241646 — intervention group
Group type: COMPARATOR
Intervention: NP (vinorelbine and cisplatin) alone
Number of subjects: 120
Study 18241646 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate combined with NP
Number of subjects: 120
Study 18241646 — intervention group
Group type: COMPARATOR
Intervention: NP alone
Number of subjects: 120
Study 15821265 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral drug therapy
Number of subjects: 0
Study 15821265 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral drug prophylaxis
Number of subjects: 0
Study 12349850 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin resistance treatment with new drugs
Number of subjects: 0
Study 12349850 — intervention group
Group type: COMPARATOR
Intervention: Insulin resistance
Number of subjects: 0
Study 10368053 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline hyclate (8.5% w/w) delivered subgingivally in a biodegradable polymer (DH)
Number of subjects: 411
Study 10368053 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP)
Number of subjects: 411
Study 10368053 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (VC)
Number of subjects: 411
Study 10368053 — intervention group
Group type: COMPARATOR
Intervention: Oral hygiene (OH)
Number of subjects: 411
Study 8665547 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (4.5 mg/day maximum)
Number of subjects: 55
Study 8665547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 8665547 — intervention group
Group type: COMPARATOR
Intervention: Pramipexole and Placebo
Number of subjects: 55
Study 2183619 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 263
Study 2183619 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 263
Study 2183619 — intervention group
Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 263
Study 2183619 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Methyldopa, Labetalol, No medication)
Number of subjects: 263
Study 7438713 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive ventilation in a Drinker respirator
Number of subjects: 5
Study 7438713 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous breathing
Number of subjects: 5
Study 31964446 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic butterfly-inlay cartilage myringoplasty
Number of subjects: 71
Study 31964446 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic push-through myringoplasty
Number of subjects: 71
Study 30111233 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (TC) classes
Number of subjects: 26
Study 30111233 — intervention group
Group type: COMPARATOR
Intervention: Electronic Tablet (ET) classes
Number of subjects: 26
Study 28072852 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer education intervention consisting of three sessions held by peers.
Number of subjects: 179
Study 28072852 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 179
Study 25864242 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined in-office and home-use desensitizing system containing 8% arginine and calcium carbonate (Test)
Number of subjects: 50
Study 25864242 — intervention group
Group type: COMPARATOR
Intervention: Conventional prophylactic paste and potassium nitrate dentifrice (Control)
Number of subjects: 50
Study 24026600 — intervention group
Group type: EXPERIMENTAL
Intervention: Pay-for-performance incentives in EHR-enabled clinics
Number of subjects: 42
Study 21681081 — intervention group
Group type: EXPERIMENTAL
Intervention: N₂O group
Number of subjects: 2050
Study 21681081 — intervention group
Group type: COMPARATOR
Intervention: N₂O-free group
Number of subjects: 2050
Study 19915221 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor (intravenous, administered 30 minutes before PCI and continued for 2 hours after PCI)
Number of subjects: 8877
Study 19915221 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (600 mg oral loading dose, administered 30 minutes before PCI)
Number of subjects: 8877
Study 19915221 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 8877
Study 19915221 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 8877
Study 17296187 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamon extract
Number of subjects: 15
Study 17296187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 15220230 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle case management (individual and group education, support, and referral by registered dietitians; cost: $350 per person)
Number of subjects: 147
Study 15220230 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle case management
Number of subjects: 147
Study 15220230 — intervention group
Group type: COMPARATOR
Intervention: Usual care (educational material)
Number of subjects: 147
Study 15220230 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 147
Study 11576938 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD) patients
Number of subjects: 23
Study 11576938 — intervention group
Group type: EXPERIMENTAL
Intervention: Predialysis patients (CRF)
Number of subjects: 23
Study 11576938 — intervention group
Group type: COMPARATOR
Intervention: Control patients (nonuremic)
Number of subjects: 23
Study 9701531 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg
Number of subjects: 40
Study 9701531 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 40
Study 9701531 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 30 mg
Number of subjects: 40
Study 9701531 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 40 mg
Number of subjects: 40
Study 9701531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7974162 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent electrostimulation with active muscle training
Number of subjects: 0
Study 7974162 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent electrostimulation without active muscle training
Number of subjects: 0
Study 7974162 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 2553528 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (1500 aPTT once daily)
Number of subjects: 300
Study 2553528 — intervention group
Group type: COMPARATOR
Intervention: Sodium heparin (5000 IU three times daily)
Number of subjects: 300
Study 2553528 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 300
Study 2553528 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 300
Study 17894044 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0
Study 17894044 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluoperazine
Number of subjects: 0
Study 31104832 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of fIPV (Group D)
Number of subjects: 1076
Study 31104832 — intervention group
Group type: COMPARATOR
Intervention: fIPV booster (Group B)
Number of subjects: 1076
Study 28899892 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioural therapy (ICBT) for 15 weeks
Number of subjects: 126
Study 28899892 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioural group therapy (CBGT) for 15 weeks
Number of subjects: 126
Study 26658938 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Treatment Assistants (CTAs) with additional half-day training and a TT screening card
Number of subjects: 59
Study 26658938 — intervention group
Group type: COMPARATOR
Intervention: Usual care CTAs
Number of subjects: 59
Study 26658938 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel screening tool
Number of subjects: 59
Study 26658938 — intervention group
Group type: COMPARATOR
Intervention: Usual care screening
Number of subjects: 59
Study 26658938 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 59
Study 23580379 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management by healthcare assistants
Number of subjects: 562
Study 23580379 — intervention group
Group type: COMPARATOR
Intervention: Control group (no case management)
Number of subjects: 562
Study 21342005 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally advanced flap (CAF) and subepithelial connective tissue graft (SCTG) using a full-thickness flap reflection
Number of subjects: 20
Study 21342005 — intervention group
Group type: COMPARATOR
Intervention: Coronally advanced flap (CAF) associated with a subepithelial connective tissue graft (SCTG) and partial-thickness flap reflection
Number of subjects: 20
Study 17588276 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg once daily
Number of subjects: 311
Study 17588276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study 15184958 — intervention group
Group type: EXPERIMENTAL
Intervention: latanoprost 0.005% + TDC
Number of subjects: 80
Study 12535752 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine treatment in patients with subclinical hypothyroidism (SCH)
Number of subjects: 124
Study 12535752 — intervention group
Group type: COMPARATOR
Intervention: Overt hypothyroidism (OH)
Number of subjects: 124
Study 12535752 — intervention group
Group type: COMPARATOR
Intervention: Subclinical hypothyroidism (SCH)
Number of subjects: 124
Study 10908004 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight models of outpatient treatment for methamphetamine dependence (treatment-as-usual)
Number of subjects: 0
Study 10908004 — intervention group
Group type: COMPARATOR
Intervention: Matrix model
Number of subjects: 0
Study 9039444 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptomycin-thiacetazone-isoniazid (STH)
Number of subjects: 0
Study 9039444 — intervention group
Group type: COMPARATOR
Intervention: Rifampin-isoniazid-pyrazinamide (RHZ)
Number of subjects: 0
Study 1538597 — intervention group
Group type: EXPERIMENTAL
Intervention: No-touch technique without any other preparation aids (Group I)
Number of subjects: 29
Study 1538597 — intervention group
Group type: COMPARATOR
Intervention: Distention at 70-120 mm Hg with balanced pH electrolyte solution (Group II)
Number of subjects: 29
Study 1538597 — intervention group
Group type: COMPARATOR
Intervention: Distention at 70-120 mm Hg with balanced pH electrolyte solution plus nitroglycerin (1 microgram/ml) (Group III)
Number of subjects: 29
Study 6377994 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Positive Pressure Breathing (IPPB) for 15 min 4 times daily
Number of subjects: 172
Study 6377994 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive Spirometry (IS) 4 times daily
Number of subjects: 172
Study 6377994 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Breathing Exercises (DBE) for 15 min 4 times daily
Number of subjects: 172
Study 6377994 — intervention group
Group type: COMPARATOR
Intervention: Control group (no respiratory treatment)
Number of subjects: 172
Study 31278814 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers (n=33)
Number of subjects: 66
Study 31278814 — intervention group
Group type: COMPARATOR
Intervention: Never-smokers (n=33)
Number of subjects: 66
Study 29423540 — intervention group
Group type: COMPARATOR
Intervention: Statins
Number of subjects: 810
Study 29423540 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitors (ACEI)
Number of subjects: 810
Study 29423540 — intervention group
Group type: COMPARATOR
Intervention: Sartans
Number of subjects: 810
Study 26526055 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group (predictive model development)
Number of subjects: 284
Study 26526055 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation group (predictive model testing)
Number of subjects: 284
Study 24901305 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g carbohydrate (sucrose) 45 min before exercise
Number of subjects: 17
Study 24901305 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 × 0.2 g · kg‐1 sodium bicarbonate (NaHCO3) 90 and 20 min before exercise
Number of subjects: 17
Study 24901305 — intervention group
Group type: COMPARATOR
Intervention: Placebo (H2O for carbohydrate group, 2 × 0.14 g · kg‐1 NaCl for sodium bicarbonate group)
Number of subjects: 17
Study 22296950 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary care program (e-health intervention and integrated care management)
Number of subjects: 212
Study 22296950 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary care program
Number of subjects: 212
Study 22296950 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical care
Number of subjects: 212
Study 20214718 — intervention group
Group type: EXPERIMENTAL
Intervention: LC 40 mg
Number of subjects: 350
Study 20214718 — intervention group
Group type: EXPERIMENTAL
Intervention: LC 80 mg
Number of subjects: 350
Study 20214718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study 18797094 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft occlusal splint therapy
Number of subjects: 40
Study 18797094 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy (muscle relaxants and analgesics)
Number of subjects: 40
Study 29092729 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaltoprofen capsule (80 mg) under fasting state
Number of subjects: 24
Study 29092729 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaltoprofen tablet (80 mg) under fasting state
Number of subjects: 24
Study 29092729 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaltoprofen capsule (80 mg) under fed state
Number of subjects: 24
Study 29092729 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaltoprofen tablet (80 mg) under fed state
Number of subjects: 24